Want to see DVA full AI Analyst Report?
DVA Stock Chart & Stats
$235.44
$1.05(0.45%)
At close: 4:00 PM EDT
$235.44
$1.05(0.45%)
Day’s Range― - ―
52-Week Range$101.00 - $247.49
Previous CloseN/A
Volume215.97K
Average Volume (3M)761.53K
Market Cap
$11.27B
Enterprise Value$29.18K
Total Cash (Recent Filing)$688.88M
Total Debt (Recent Filing)$10.78B
Price to Earnings (P/E)15.3
Beta0.34
Next Earnings
Oct 23, 2026EPS Estimate
3.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.63
Shares Outstanding63,800,000
10 Day Avg. Volume607,188
30 Day Avg. Volume761,531
Financial Highlights & Ratios
PEG Ratio-0.99
Price to Book (P/B)-15.02
Price to Sales (P/S)0.72
P/FCF Ratio7.46
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$238.80Price Target Upside1.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)14.78
Revenue Forecast (FY)$14.09B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistently strong operating cash flow and sharply rising free cash flow provide durable internal funding for capex, clinical initiatives and share repurchases. Over a 2–6 month horizon this supports strategic flexibility to service debt, sustain investment and prioritize high-return uses despite heavy gross leverage.
Sustained Revenue And Margin ProfileMeaningful trailing revenue growth and solid operating/EBITDA margins reflect durable demand for outpatient dialysis and service stickiness. A resilient top line and positive margins help the company absorb reimbursement headwinds and fund efficiency programs, supporting medium-term earnings stability.
Clinical/competitive Advantage — Expanded HDClinical evidence plus secured supply enable DaVita to roll out expanded HD at scale without significant capital spending. That operationally feasible, lower-capex therapy can improve clinical differentiation, reduce reliance on costlier treatments and deliver durable clinical and cost benefits as adoption grows over the next few years.
Bears Say
High Leverage / Negative EquityVery large debt and an equity deficit materially constrain financial flexibility, elevating refinancing and interest-rate risk. Even with strong cash generation, deleveraging is likely to be gradual, limiting capacity for large M&A, meaningfully faster buybacks, or to absorb sizable reimbursement or regulatory shocks over the medium term.
Commercial Mix / ACA HeadwindDeclining ACA enrollment and effectuation shifts are a structural payer-mix risk that reduce higher-rate commercial revenue. A multi-year commercial mix deterioration lowers revenue-per-treatment and compresses margins unless offset by new commercial wins or higher utilization, making earnings growth harder to sustain beyond temporary volume gains.
Rising Patient Care And Operating CostsSustained patient care cost growth and elevated G&A pressure reduce margin leverage from volume growth. If labor, drug and supply cost trends persist, the company will face ongoing margin compression and slower free cash flow expansion unless it achieves structural efficiency gains or secures higher reimbursement over the medium term.
DaVita News
DVA FAQ
What was DaVita’s price range in the past 12 months?
DaVita lowest stock price was $101.00 and its highest was $247.49 in the past 12 months.
What is DaVita’s market cap?
DaVita’s market cap is $11.27B.
When is DaVita’s upcoming earnings report date?
DaVita’s upcoming earnings report date is Oct 23, 2026 which is in 64 days.
How were DaVita’s earnings last quarter?
DaVita released its earnings results on Aug 04, 2026. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.882 by $0.138.
Is DaVita overvalued?
According to Wall Street analysts DaVita’s price is currently Undervalued.
Does DaVita pay dividends?
DaVita does not currently pay dividends.
What is DaVita’s EPS estimate?
DaVita’s EPS estimate is 3.58.
How many shares outstanding does DaVita have?
DaVita has 63,800,000 shares outstanding.
What happened to DaVita’s price movement after its last earnings report?
DaVita reported an EPS of $4.02 in its last earnings report, beating expectations of $3.882. Following the earnings report the stock price went down -17.238%.
Which hedge fund is a major shareholder of DaVita?
Currently, no hedge funds are holding shares in DVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DaVita Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$238.80 (1.43% Upside)
$238.80 (1.43% Upside)
Blogger Sentiment
Bullish
DVA Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 7.4%
Last 30 Days ▲ 7.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1.24%
Trailing 12-Months
Company Description
DaVita
DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.
DVA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: clear clinical progress (phosphate binder transition, MOTheR results, expanded HD supply and deployment) and solid near-term financials (Q2 OI, EPS, free cash flow, buybacks, leverage within target) support confidence in the strategy. However, near-term revenue-per-treatment pressure, ACA-related commercial mix headwinds (~$40M in 2026, ~$70M in 2027), elevated patient care cost growth YTD (>3%), and some operational noise (missed treatments, smaller Fresenius pickup) temper upside and create uncertainty for margin expansion in the back half of the year and into 2027.View all DVA earnings summariesDVA Revenue Breakdown
85.99% U.S. dialysis
14.01% Ancillary services
DVA Stock 12 Month Forecast
Average Price Target
$238.80
▲(1.43% Upside)
Technical Analysis
Fresenius Medical Care
―
HCA Healthcare
―
Encompass Health
―
Tenet Healthcare
―
The Ensign Group
―
Ownership Overview
47.01% Insiders
10.89% Mutual Funds
4.16% Other Institutional Investors
21.73% Public Companies and
Individual Investors